Search Results for: SRC

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
CBL Cbl proto-oncogene
  • Interleukin-6 signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Spry regulation of FGF signaling
  • Regulation of KIT signaling
  • EGFR downregulation
  • TGF-beta receptor signaling activates SMADs
  • Constitutive Signaling by EGFRvIII
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Negative regulation of MET activity
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Negative regulation of FLT3
  • FLT3 signaling by CBL mutants
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
CCNA1 cyclin A1
  • G0 and Early G1
  • Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes
  • Telomere Extension By Telomerase
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • Ub-specific processing proteases
  • Processing of DNA double-strand break ends
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • G2 Phase
  • Orc1 removal from chromatin
  • CDK-mediated phosphorylation and removal of Cdc6
  • G1/S-Specific Transcription
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Cyclin A/B1/B2 associated events during G2/M transition
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A:Cdk2-associated events at S phase entry
ITGB3 integrin subunit beta 3
  • Platelet degranulation
  • Elastic fibre formation
  • PECAM1 interactions
  • Molecules associated with elastic fibres
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • Syndecan interactions
  • Syndecan interactions
  • ECM proteoglycans
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • VEGFA-VEGFR2 Pathway
  • Signal transduction by L1
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Abciximab
  • Eptifibatide
  • Antithymocyte immunoglobulin (rabbit)
  • Levothyroxine
  • Tirofiban
  • Resveratrol
  • Lefradafiban
  • LM-609
  • Fradafiban
  • Ferric maltol
  • Glanzmann thrombasthenia
  • Allograft rejection
KIT KIT proto-oncogene, receptor tyrosine kinase
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Regulation of KIT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Dasatinib-resistant KIT mutants
  • Imatinib-resistant KIT mutants
  • KIT mutants bind TKIs
  • Masitinib-resistant KIT mutants
  • Nilotinib-resistant KIT mutants
  • Regorafenib-resistant KIT mutants
  • Signaling by kinase domain mutants of KIT
  • Sunitinib-resistant KIT mutants
  • Signaling by juxtamembrane domain KIT mutants
  • Sorafenib-resistant KIT mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by extracellular domain mutants of KIT
  • Sorafenib
  • Imatinib
  • Dasatinib
  • Sunitinib
  • Phosphonotyrosine
  • Nilotinib
  • XL820
  • OSI-930
  • ABT-869
  • Pazopanib
  • Midostaurin
  • Regorafenib
  • Ponatinib
  • Lenvatinib
  • Ancestim
  • Fostamatinib
  • Erdafitinib
  • Amuvatinib
  • Pexidartinib
  • Ripretinib
  • Avapritinib
  • Piebaldism
  • Acute myeloid leukemia (AML)
PRKCA protein kinase C alpha
  • Calmodulin induced events
  • Disinhibition of SNARE formation
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • EGFR Transactivation by Gastrin
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Syndecan interactions
  • Acetylcholine regulates insulin secretion
  • Ca2+ pathway
  • Trafficking of GluR2-containing AMPA receptors
  • G alpha (z) signalling events
  • Depolymerisation of the Nuclear Lamina
  • HuR (ELAVL1) binds and stabilizes mRNA
  • WNT5A-dependent internalization of FZD4
  • VEGFR2 mediated cell proliferation
  • RHO GTPases Activate NADPH Oxidases
  • Response to elevated platelet cytosolic Ca2+
  • RET signaling
  • ROBO receptors bind AKAP5
  • ROBO receptors bind AKAP5
  • Phosphatidyl serine
  • Vitamin E
  • Tamoxifen
  • Ingenol mebutate
  • Aprinocarsen
  • Midostaurin
  • Perifosine
  • Ellagic acid
  • Bryostatin 1
  • alpha-Tocopherol succinate
  • D-alpha-Tocopherol acetate
CDC37 cell division cycle 37, HSP90 cochaperone
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Constitutive Signaling by EGFRvIII
  • Regulation of necroptotic cell death
  • Downregulation of ERBB2 signaling
  • RHOBTB2 GTPase cycle
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
PTK2 protein tyrosine kinase 2
  • Apoptotic cleavage of cellular proteins
  • Regulation of actin dynamics for phagocytic cup formation
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • NCAM signaling for neurite out-growth
  • NCAM signaling for neurite out-growth
  • Signal regulatory protein family interactions
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate WASPs and WAVEs
  • RAF/MAP kinase cascade
  • MET activates PTK2 signaling
  • Extra-nuclear estrogen signaling
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • FCGR3A-mediated phagocytosis
  • Endostatin
  • 7-PYRIDIN-2-YL-N-(3,4,5-TRIMETHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE
  • 2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE
  • Fostamatinib
GAB2 GRB2 associated binding protein 2
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RET signaling
  • Interleukin-15 signaling
  • Interleukin receptor SHC signaling
  • FLT3 Signaling
  • FLT3 Signaling
  • STAT5 Activation
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
PAK2 p21 (RAC1) activated kinase 2
  • Nef and signal transduction
  • Generation of second messenger molecules
  • Regulation of PAK-2p34 activity by PS-GAP/RHG10
  • Regulation of activated PAK-2p34 by proteasome mediated degradation
  • Stimulation of the cell death response by PAK-2p34
  • FCERI mediated MAPK activation
  • FCERI mediated MAPK activation
  • CD28 dependent Vav1 pathway
  • Ephrin signaling
  • Sema3A PAK dependent Axon repulsion
  • Activation of RAC1
  • VEGFA-VEGFR2 Pathway
  • Smooth Muscle Contraction
  • VEGFR2 mediated vascular permeability
  • CD209 (DC-SIGN) signaling
  • RHO GTPases activate PAKs
  • RHO GTPases activate PAKs
  • MAPK6/MAPK4 signaling
  • Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
  • Fostamatinib
PDPK1 3-phosphoinositide dependent protein kinase 1
  • GPVI-mediated activation cascade
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Activation of AKT2
  • Downstream TCR signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated NF-kB activation
  • Integrin signaling
  • CD28 dependent PI3K/Akt signaling
  • G beta:gamma signalling through PI3Kgamma
  • RSK activation
  • VEGFR2 mediated vascular permeability
  • VEGFR2 mediated cell proliferation
  • CLEC7A (Dectin-1) signaling
  • RHO GTPases activate PKNs
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Regulation of TP53 Degradation
  • Estrogen-stimulated signaling through PRKCZ
  • Estrogen-stimulated signaling through PRKCZ
  • Celecoxib
  • Inositol 1,3,4,5-Tetrakisphosphate
  • 7-Hydroxystaurosporine
  • Bisindolylmaleimide VIII
  • Staurosporine
  • Bisindolylmaleimide I
  • Dexfosfoserine
  • 10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine
  • 5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE
  • 1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA
  • 2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine
  • 3-(1H-indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidinyl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione
  • 3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE
  • Fostamatinib
PTPN6 protein tyrosine phosphatase non-receptor type 6
  • GPVI-mediated activation cascade
  • Regulation of KIT signaling
  • PECAM1 interactions
  • Costimulation by the CD28 family
  • PD-1 signaling
  • Signal regulatory protein family interactions
  • Platelet sensitization by LDL
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • CD22 mediated BCR regulation
  • Neutrophil degranulation
  • Interferon gamma signaling
  • Regulation of IFNG signaling
  • Interleukin-37 signaling
  • Interferon alpha/beta signaling
  • Interleukin receptor SHC signaling
  • Regulation of IFNA signaling
  • Growth hormone receptor signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Tiludronic acid
MET MET proto-oncogene, receptor tyrosine kinase
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D mediated inhibition of cell attachment and migration
  • RAF/MAP kinase cascade
  • MET Receptor Activation
  • Negative regulation of MET activity
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates RAS signaling
  • MET activates PI3K/AKT signaling
  • MET activates PTPN11
  • MET activates PTK2 signaling
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • MET interacts with TNS proteins
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • MET activates STAT3
  • MECP2 regulates neuronal receptors and channels
  • K-252a
  • SGX-523
  • 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide
  • N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide
  • 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide
  • N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide
  • 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol
  • AMG-208
  • 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE
  • Crizotinib
  • Cabozantinib
  • Capmatinib
  • Fostamatinib
  • Tivantinib
  • Brigatinib
  • Amuvatinib
  • Renal cell carcinoma
  • Cholangiocarcinoma
  • Gastric cancer
PIK3R3 phosphoinositide-3-kinase regulatory subunit 3
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Costimulation by the CD28 family
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RET signaling
  • Extra-nuclear estrogen signaling
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Isoprenaline
  • SF1126
STAT1 signal transducer and activator of transcription 1
  • Interleukin-6 signaling
  • ISG15 antiviral mechanism
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • Interleukin-4 and Interleukin-13 signaling
  • Interleukin-20 family signaling
  • Regulation of RUNX2 expression and activity
  • Interleukin-35 Signalling
  • Interleukin-9 signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • Interleukin-27 signaling
  • Interleukin-21 signaling
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Growth hormone receptor signaling
  • Chronic Mucocutaneous Candidiasis (CMC); Familial candidiasis (CANDF)
  • IFN-gamma/IL-12 axis, including the following five diseases: IL-12 p40 subunit deficiency; IL-12 receptor (IL-12R) beta1 chain deficiency; IFN-gamma receptor (IFN gamma R) alpha chain deficiency; IFN-gamma receptor (IFN gamma R) beta chain deficiency; STAT-1 deficiency
YWHAE tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon
  • Activation of BAD and translocation to mitochondria
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Signaling by Hippo
  • NADE modulates death signalling
  • Regulation of PLK1 Activity at G2/M Transition
  • Regulation of HSF1-mediated heat shock response
  • HSF1 activation
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • RHO GTPases activate PKNs
  • TP53 Regulates Metabolic Genes
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • AURKA Activation by TPX2
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • RAB GEFs exchange GTP for GDP on RABs
  • Fusicoccin
  • Phenethyl Isothiocyanate
  • Lissencephaly (LIS); Miller-Dieker syndrome (MDLS)
CDKN1B cyclin dependent kinase inhibitor 1B
  • SCF(Skp2)-mediated degradation of p27/p21
  • AKT phosphorylates targets in the cytosol
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • RHO GTPases activate CIT
  • Constitutive Signaling by AKT1 E17K in Cancer
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates Cell Cycle
  • FLT3 Signaling
  • FOXO-mediated transcription of cell cycle genes
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Prostate cancer
CLTC clathrin heavy chain
  • Entry of Influenza Virion into Host Cell via Endocytosis
  • Retrograde neurotrophin signalling
  • Retrograde neurotrophin signalling
  • Gap junction degradation
  • Formation of annular gap junctions
  • MHC class II antigen presentation
  • EPH-ephrin mediated repulsion of cells
  • Lysosome Vesicle Biogenesis
  • Recycling pathway of L1
  • Recycling pathway of L1
  • WNT5A-dependent internalization of FZD4
  • WNT5A-dependent internalization of FZD2, FZD5 and ROR2
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • VLDLR internalisation and degradation
  • LDL clearance
DLG4 discs large MAGUK scaffold protein 4
  • Signaling by ERBB4
  • Trafficking of AMPA receptors
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • NrCAM interactions
  • Activation of Ca-permeable Kainate Receptor
  • RHO GTPases activate CIT
  • RAF/MAP kinase cascade
  • LGI-ADAM interactions
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Guanidine
  • Guanosine-5'-Monophosphate
CD36 CD36 molecule
  • Platelet degranulation
  • Cross-presentation of particulate exogenous antigens (phagosomes)
  • ER-Phagosome pathway
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • Toll Like Receptor TLR6:TLR2 Cascade
  • PPARA activates gene expression
  • Scavenging by Class B Receptors
  • Scavenging by Class B Receptors
  • Transcriptional regulation of white adipocyte differentiation
  • Intracellular metabolism of fatty acids regulates insulin secretion
  • MyD88 deficiency (TLR2/4)
  • IRAK4 deficiency (TLR2/4)
  • Regulation of TLR by endogenous ligand
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
ESR1 estrogen receptor 1
  • Nuclear signaling by ERBB4
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Ovarian tumor domain proteases
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • RUNX1 regulates estrogen receptor mediated transcription
  • ESR-mediated signaling
  • RUNX1 regulates transcription of genes involved in WNT signaling
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • Extra-nuclear estrogen signaling
  • Estrogen-dependent gene expression
  • Diethylstilbestrol
  • Chlorotrianisene
  • Conjugated estrogens
  • Desogestrel
  • Levonorgestrel
  • Progesterone
  • Lindane
  • Raloxifene
  • Toremifene
  • Medroxyprogesterone acetate
  • Testosterone
  • Mitotane
  • Estrone
  • Tamoxifen
  • Hexachlorophene
  • Estradiol
  • Ethynodiol diacetate
  • Dobutamine
  • Clomifene
  • Dienestrol
  • Fulvestrant
  • Norgestimate
  • Ethinylestradiol
  • Melatonin
  • Trilostane
  • Naloxone
  • Fluoxymesterone
  • Estramustine
  • Mestranol
  • Danazol
  • Oxybenzone
  • Allylestrenol
  • Zinc
  • Genistein
  • Prasterone
  • Benzophenone
  • Equilin
  • Compound 19
  • Resveratrol
  • Compound 18
  • Phthalic Acid
  • Pyrazole
  • Stanolone
  • Naringenin
  • Compound 4-D
  • 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Quercetin
  • Afimoxifene
  • 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Estriol
  • Estrone sulfate
  • Quinestrol
  • Phenolphthalein
  • Permethrin
  • Ospemifene
  • AP1081
  • Custirsen
  • NP-50301
  • CHF 4227
  • TAS-108
  • Lasofoxifene
  • Arzoxifene
  • Elacestrant
  • Bazedoxifene
  • Methyltestosterone
  • beta-Naphthoflavone
  • 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
  • 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
  • (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
  • (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
  • 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • Hexestrol
  • dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
  • Erteberel
  • N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
  • 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
  • DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
  • 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
  • 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
  • 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol
  • Tibolone
  • Eugenol
  • Synthetic Conjugated Estrogens, A
  • Synthetic Conjugated Estrogens, B
  • Polyestradiol phosphate
  • Norethynodrel
  • Octocrylene
  • Homosalate
  • Enzacamene
  • Zeranol
  • Ractopamine
  • Gestrinone
  • Propyl Gallate
  • 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol
  • Testosterone cypionate
  • Testosterone enanthate
  • Testosterone undecanoate
  • Stanolone acetate
  • Estradiol acetate
  • Estradiol benzoate
  • Estradiol cypionate
  • Estradiol dienanthate
  • Estradiol valerate
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Estriol tripropionate
  • Fluoroestradiol F-18

Page 3 out of 16 pages